

Effect of Age on Stroke Prevention Therapy in Patients

Stroke

40, 1410-1416

DOI: [10.1161/strokeaha.108.526988](https://doi.org/10.1161/strokeaha.108.526988)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Predicting and preventing stroke after transient ischemic attack. Expert Review of Neurotherapeutics, 2009, 9, 1159-1170.	2.8	10
2	Evaluation and management of stroke. Hematology American Society of Hematology Education Program, 2009, 2009, 293-301.	2.5	5
3	Atrial fibrillation, stroke prevention therapy and aging. Nature Reviews Cardiology, 2009, 6, 448-450.	13.7	15
4	Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms. Seminars in Thrombosis and Hemostasis, 2009, 35, 554-559.	2.7	22
5	Anticoagulant Management in Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 543-547.	2.7	1
6	Secondary prevention of stroke. Expert Review of Cardiovascular Therapy, 2009, 7, 1103-1115.	1.5	23
7	Lang zullen we leven. Huisarts En Wetenschap, 2009, 52, 317-317.	0.0	1
10	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest, 2010, 137, 263-272.	0.8	5,657
12	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurology, The, 2010, 9, 273-284.	10.2	83
13	Avances en la prevención de la isquemia cerebral por fibrilación auricular. Neurología, 2010, 25, 401-408.	0.7	13
14	Optimal loading dose for the initiation of warfarin: a systematic review. BMC Cardiovascular Disorders, 2010, 10, 18.	1.7	23
15	Anticoagulation intensity for elderly atrial fibrillation patients: Should we use a conventional INR target (2.0 to 3.0) or a lower range?. Thrombosis and Haemostasis, 2010, 103, 254-256.	3.4	6
16	Prevention of Stroke in Patients with Atrial Fibrillation: The Role of New Antiarrhythmic and Antithrombotic Drugs. Cerebrovascular Diseases, 2010, 30, 314-322.	1.7	8
17	Prevention of cardioembolic stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2010, 8, 1405-1415.	1.5	6
20	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2010, 56, 827-837.	2.8	206
22	Should all patients with non-valvular atrial fibrillation be anticoagulated?. International Journal of Cardiology, 2010, 143, 8-15.	1.7	7
23	Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. American Journal of Medicine, 2010, 123, 638-645.e4.	1.5	839
24	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest, 2010, 138, 1093-1100.	0.8	3,810

#	ARTICLE	IF	CITATIONS
25	Stroke Prevention in Atrial Fibrillation. <i>Drugs and Aging</i> , 2010, 27, 859-870.	2.7	8
26	New concepts and approaches to stroke prevention in the new European Society of Cardiology guidelines for the management of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1643-1647.	1.5	2
27	Assess underlying risks when choosing a treatment to prevent strokes in patients with atrial fibrillation. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 14-17.	0.6	0
28	The role of aspirin for stroke prevention in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2011, 8, 602-606.	13.7	106
29	Use of Oral Anticoagulant for Secondary Prevention of Stroke in Very Elderly Patients With Atrial Fibrillation: An Observational Study. <i>International Journal of Gerontology</i> , 2011, 5, 45-48.	0.6	7
30	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d124-d124.	2.3	1,143
31	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 739-749.	3.4	393
32	New Insights into Anticoagulation in Atrial Fibrillation. <i>Journal of Arrhythmia</i> , 2011, 27, 186-192.	1.2	0
33	Anticoagulant Therapy in Very Old Patients. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2011, 11, 24-29.	0.7	1
35	Epidemiological Aspects of Stroke in Very Old Patients. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2011, 11, 2-5.	0.7	11
36	The Case for an Elderly Targeted Stroke Management. <i>Frontiers in Neurology</i> , 2011, 2, 89.	2.4	4
37	A Tutorial on Methods to Estimating Clinically and Policy-Meaningful Measures of Treatment Effects in Prospective Observational Studies: A Review. <i>International Journal of Biostatistics</i> , 2011, 7, 1-32.	0.7	69
38	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 39-48.	3.8	240
39	Atrial fibrillation and upper limb thromboembolism: a national cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1738-1743.	3.8	14
40	Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 344-351.	3.8	81
42	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. <i>Future Cardiology</i> , 2011, 7, 415-423.	1.2	6
43	Future epidemic impact of atrial fibrillation and a new interventional strategy for stroke prophylaxis. <i>Future Cardiology</i> , 2011, 7, 219-226.	1.2	3
44	Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. <i>Age and Ageing</i> , 2011, 40, 653-655.	1.6	13

#	ARTICLE	IF	CITATIONS
45	A New Landscape for Stroke Prevention in Atrial Fibrillation. Stroke, 2011, 42, 3316-3322.	2.0	26
46	Intracerebral Hemorrhage and Warfarin. Stroke, 2011, 42, 2383-2384.	2.0	2
47	Challenges of stroke prevention in patients with atrial fibrillation in clinical practice. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 739-746.	0.5	7
48	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace, 2011, 13, 723-746.	1.7	197
49	Advances in the management of atrial fibrillation. Clinical Medicine, 2012, 12, 544-552.	1.9	0
50	Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease. Current Pharmaceutical Design, 2012, 18, 5362-5378.	1.9	8
51	Optimal loading dose of warfarin for the initiation of oral anticoagulation. The Cochrane Library, 2021, 2021, CD008685.	2.8	20
52	Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ, The, 2012, 344, e3522-e3522.	6.0	215
53	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 312-318.	4.8	123
54	Use of Secondary Medical Prophylaxis and Clinical Outcome Among Patients With Ischemic Stroke. Stroke, 2012, 43, 802-807.	2.0	13
55	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. Chest, 2012, 141, 147-153.	0.8	96
56	Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. Stroke, 2012, 43, 2048-2054.	2.0	36
58	Managing anticoagulation in patients receiving implantable cardiac devices. Future Cardiology, 2012, 8, 393-411.	1.2	1
59	Anticoagulation for Non-Valvular Atrial Fibrillation in Older People. Journal of Pharmacy Practice and Research, 2012, 42, 228-234.	0.8	0
60	Stroke and Thromboembolism in Atrial Fibrillation. Circulation Journal, 2012, 76, 2289-2304.	1.6	131
61	Atrial fibrillation. Lancet, The, 2012, 379, 648-661.	13.7	337
62	Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American Heart Journal, 2012, 164, 607-615.	2.7	23
63	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 627-633.	0.6	14

#	ARTICLE	IF	CITATIONS
66	Transcatheter left atrial appendage closure for stroke prevention among atrial fibrillation patients. Expert Review of Cardiovascular Therapy, 2012, 10, 819-821.	1.5	4
67	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.7	2,319
68	Valor predictivo de la escala CHA2DS2-VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. Revista Española De Cardiología, 2012, 65, 627-633.	1.2	41
69	Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study. Thrombosis Research, 2012, 130, 21-26.	1.7	29
70	Long term treatment of atrial fibrillation in elderly patients: A decision analysis. International Journal of Cardiology, 2012, 155, 102-109.	1.7	2
71	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 680-688.	2.2	198
72	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,144
73	Use of the CHA ₂ DS ₂ -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation, 2012, 126, 860-865.	1.6	327
75	In-Depth Review of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation. American Medical Journal, 2012, 3, 100-103.	1.0	0
76	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.8	891
77	The CHADS ₂ versus the New CHA ₂ DS ₂ -VASc Scoring Systems for Guiding Antithrombotic Treatment of Patients with Atrial Fibrillation: Review of the Literature and Recommendations for Use. Pharmacotherapy, 2012, 32, 285-296.	2.6	41
78	Atrial Fibrillation and Vascular Disease—A Bad Combination. Clinical Cardiology, 2012, 35, 15-20.	1.8	27
79	Can We Predict Stroke in Atrial Fibrillation?. Clinical Cardiology, 2012, 35, 21-7.	1.8	31
80	The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thrombosis and Haemostasis, 2012, 107, 1172-1179.	3.4	414
81	Novel Anticoagulants for Atrial Fibrillation. Angiology, 2012, 63, 164-170.	1.8	13
82	Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews, 2012, 17, 597-613.	3.9	38
83	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. Journal of Internal Medicine, 2012, 271, 15-24.	6.0	48
84	Underuse of Antithrombotic Therapy Caused High Incidence of Ischemic Stroke in Patients with Atrial Fibrillation. International Journal of Stroke, 2012, 7, 112-117.	5.9	19

#	ARTICLE	IF	CITATIONS
85	Hemorrhage after Ischemic Stroke – Relation to Age and Previous Hemorrhage in a Nationwide Cohort of 58 868 Patients. International Journal of Stroke, 2013, 8, 80-86.	5.9	10
86	Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations. European Journal of Clinical Pharmacology, 2013, 69, 245-253.	1.9	26
87	Novel oral anticoagulants in non-valvular atrial fibrillation. Best Practice and Research in Clinical Haematology, 2013, 26, 115-129.	1.7	27
88	New oral anticoagulants in elderly patients. Best Practice and Research in Clinical Haematology, 2013, 26, 215-224.	1.7	60
89	The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. Journal of Cardiovascular Translational Research, 2013, 6, 388-397.	2.4	5
90	Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population. Clinical Therapeutics, 2013, 35, 1536-1545.e1.	2.5	18
91	Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace, 2013, 15, 773-774.	1.7	2
92	Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiology and Therapy, 2013, 2, 135-149.	2.6	37
94	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Revista Española De Cardiología, 2013, 66, 54.e1-54.e24.	1.2	14
96	Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study. European Journal of Internal Medicine, 2013, 24, 318-323.	2.2	25
97	CHA2DS2-VASc and HASBLED scores: Implications for thromboembolic prophylaxis in the elderly with atrial fibrillation. European Geriatric Medicine, 2013, 4, 67-72.	2.8	1
98	Thromboprophylaxis in the oldest old with atrial fibrillation: Between Scylla and Charybdis. European Journal of Internal Medicine, 2013, 24, 285-287.	2.2	12
99	Atrial fibrillation and stroke prevention: is warfarin still an option? Yes. Journal of Neural Transmission, 2013, 120, 1447-1451.	2.8	5
100	Nouveaux anticoagulants oraux. Actualites Pharmaceutiques, 2013, 52, 55-58.	0.0	0
101	Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin. Stroke, 2013, 44, 1329-1336.	2.0	95
102	Intensive risk factor control in stroke prevention. F1000prime Reports, 2013, 5, 42.	5.9	11
103	Impact of comorbidity on medication use in elderly patients with cardiovascular diseases: the OCTOCARDIO study. European Journal of Preventive Cardiology, 2013, 20, 524-530.	1.8	17
104	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1619-1629.	1.5	15

#	ARTICLE	IF	CITATIONS
105	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. Expert Review of Cardiovascular Therapy, 2013, 11, 77-90.	1.5	10
106	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. European Heart Journal, 2013, 34, 1041-1049.	2.2	141
107	Stroke Prevention With Oral Anticoagulation Therapy in Patients With Atrial Fibrillation. Circulation Journal, 2013, 77, 1380-1388.	1.6	35
108	Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?. Clinical Interventions in Aging, 2014, 9, 1091.	2.9	30
109	Differences among western European countries in anticoagulation management of atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 833-841.	3.4	96
110	FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW. Rational Pharmacotherapy in Cardiology, 2014, 10, 416-420.	0.8	0
111	Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace, 2014, 16, 631-638.	1.7	73
112	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal, 2014, 35, 1864-1872.	2.2	303
113	Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: Cross-sectional population database study. European Journal of General Practice, 2014, 20, 181-189.	2.0	11
114	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Focus in the Geriatric Population. The Consultant Pharmacist, 2014, 29, 169-178.	0.4	5
115	Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. Haemophilia, 2014, 20, 682-686.	2.1	36
116	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
117	Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation. Stroke, 2014, 45, 1331-1337.	2.0	25
118	Evaluation and Prevention of Cardioembolic Stroke. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 309-322.	0.8	3
119	Screening for undiagnosed atrial fibrillation in the community. Current Opinion in Cardiology, 2014, 29, 28-35.	1.8	20
120	Prevalence and management of atrial fibrillation in primary care: a case study. Primary Health Care Research and Development, 2014, 15, 355-361.	1.2	3
121	Increased Risk of First-Ever Stroke in Younger Patients With Atrial Fibrillation Not Recommended for Antithrombotic Therapy by Current Guidelines: A Population-Based Study in an East Asian Cohort of 22 Million People. Mayo Clinic Proceedings, 2014, 89, 1487-1497.	3.0	13
122	Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation-Related Embolic Vascular Events. Circulation, 2014, 130, 1236-1244.	1.6	145

#	ARTICLE	IF	CITATIONS
123	Comment Ã©valuer le risque ischÃ©mique et hÃ©morragique cÃ©rÃ©bral dans la fibrillation atriale ? Place des approches morphologiques et biologiques. Archives of Cardiovascular Diseases Supplements, 2014, 6, 120-131.	0.0	0
124	Impact of Atrial Fibrillation and Inadequate Antithrombotic Management on Mortality in Acute Neurovascular Syndrome. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2256-2264.	1.6	5
125	Impact of Gender on the Prognosis of Patients With Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 957-962.	1.6	57
126	Drug Therapies for Stroke Prevention in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2014, 6, 61-78.	1.7	0
127	Research into practice: management of atrial fibrillation in general practice. British Journal of General Practice, 2014, 64, 540-542.	1.4	4
128	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Riskâ€”Score Acronyms (CHADS ₂ , CHA ₂ DS ₂ -â€”VASc, R ₂ CHADS ₂), Tj ETQ, 1 0.784314 rgB	1.8	14
129	Vitamin K for improved anticoagulation control in patients receiving warfarin. The Cochrane Library, 2014, , CD009917.	2.8	4
130	Why do we need observational studies of everyday patients in the real-life setting?: TableÂ1. European Heart Journal Supplements, 2015, 17, D2-D8.	0.1	101
131	â€œTo treat or not to treat very elderly naÃ¯ve patients with atrial fibrillation with vitamin K antagonistsâ€• Internal and Emergency Medicine, 2015, 10, 765-767.	2.0	0
132	Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?. Medicine (United States), 2015, 94, e1627.	1.0	6
133	Stroke Prevention in Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 313, 1950.	7.4	258
134	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2015, 15, 323-335.	2.2	9
135	To treat or not to treat very elderly naÃ¯ve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. Internal and Emergency Medicine, 2015, 10, 795-804.	2.0	17
136	Conundrums for Atrial Fibrillation Management in Older Adults. Current Geriatrics Reports, 2015, 4, 368-376.	1.1	0
137	Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. Cerebrovascular Diseases, 2015, 40, 175-181.	1.7	47
138	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. European Heart Journal, 2015, 36, 653-656.	2.2	58
139	Antithrombotic Management of Atrial Fibrillation in the Elderly. Medical Clinics of North America, 2015, 99, 417-430.	2.5	16
140	Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. Journal of the Saudi Heart Association, 2015, 27, 31-43.	0.4	15

#	ARTICLE	IF	CITATIONS
141	Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm. Journal of the American Medical Directors Association, 2015, 16, 358-364.	2.5	41
142	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. Journal of Internal Medicine, 2015, 278, 1-18.	6.0	64
143	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age and Ageing, 2015, 44, 874-878.	1.6	57
144	Treatment of Nonagenarians With Atrial Fibrillation: Insights From the Berlin Atrial Fibrillation (BAF) Registry. Journal of the American Medical Directors Association, 2015, 16, 969-972.	2.5	14
145	Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Current Medical Research and Opinion, 2015, 31, 603-614.	1.9	32
146	Misconceptions and Facts About Atrial Fibrillation. American Journal of Medicine, 2015, 128, 938-942.	1.5	9
147	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 683-695.	2.4	9
148	Stroke Medicine. , 2015, , .		0
149	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. Drugs, 2015, 75, 1627-1644.	10.9	37
150	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation. Stroke, 2015, 46, 3202-3207.	2.0	13
152	Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. European Journal of Internal Medicine, 2015, 26, e47-e48.	2.2	1
153	Restarting antithrombotic drugs after gastrointestinal haemorrhage in people with atrial fibrillation. BMJ, The, 2015, 351, h6104-h6104.	6.0	1
154	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. Stroke, 2015, 46, 143-150.	2.0	116
155	Antiplatelet therapy is not a safer alternative to oral anticoagulants, even in older hospital-discharged patients with atrial fibrillation. Geriatric Care, 2016, 2, .	0.2	1
156	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. Heart International, 2016, 11, heartint.500023.	1.4	10
157	Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient Preference and Adherence, 2016, 10, 795.	1.8	8
158	Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea. Journal of		

#	ARTICLE	IF	CITATIONS
160	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. Journal of the American Geriatrics Society, 2016, 64, 1054-1060.	2.6	19
161	Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC Research Notes, 2016, 9, 507.	1.4	8
162	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implementation Science, 2016, 11, 159.	6.9	11
163	Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation. Chest, 2016, 149, 401-412.	0.8	80
164	The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace, 2017, 19, euw093.	1.7	24
165	Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements, 2016, 18, D1-D6.	0.1	7
166	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	1.5	24
167	Minimizing the Risk of Bleeding with NOACs in the Elderly. Drugs and Aging, 2016, 33, 491-500.	2.7	36
168	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
169	Risk Stratification in Atrial Fibrillation and Observation Unit Entry. Contemporary Cardiology, 2016, , 125-131.	0.1	0
170	Short Stay Management of Atrial Fibrillation. Contemporary Cardiology, 2016, , .	0.1	1
171	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
172	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
173	Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services. Internal Medicine Journal, 2016, 46, 1166-1171.	0.8	1
174	New concepts for anticoagulant therapy in persons with hemophilia. Blood, 2016, 128, 2471-2474.	1.4	39
176	Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 279-284.	1.5	10
177	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Canadian Journal of Cardiology, 2016, 32, 1108-1116.	1.7	6
178	Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. American Heart Journal, 2016, 176, 17-27.	2.7	42

#	ARTICLE	IF	CITATIONS
180	Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 1803-1810.	2.0	86
181	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016, 173, 143-158.	2.7	12
182	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1.	1.5	49
183	European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 460-473.	1.8	54
184	Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China. <i>Stroke</i> , 2016, 47, 464-470.	2.0	58
185	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	1.6	91
186	Real-World Impact of Setting a Narrow International Normalized Ratio Target Range in the Management of Older Adult Patients on Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 528-534.	1.7	2
187	Características y tratamiento antitrombótico de los pacientes ancianos con fibrilación auricular no valvular hospitalizados en Medicina Interna. Registro NONAVASC. <i>Medicina Clínica</i> , 2017, 148, 204-210.	0.6	24
189	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	2.9	78
190	Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1500-1510.	3.8	29
191	Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	1.9	30
192	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 425-435.	2.0	6
193	Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 204-210.	0.2	4
194	Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. <i>European Journal of Internal Medicine</i> , 2017, 41, 18-27.	2.2	26
195	Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. <i>Current Medical Research and Opinion</i> , 2017, 33, 631-638.	1.9	0
196	Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. <i>BMJ Open</i> , 2017, 7, e015363.	1.9	38
197	Atrial fibrillation decision support tool: Population perspective. <i>American Heart Journal</i> , 2017, 194, 49-60.	2.7	9
198	Pre-stroke physical activity is associated with fewer post-stroke complications, lower mortality and a better long-term outcome. <i>European Journal of Neurology</i> , 2017, 24, 1525-1531.	3.3	34

#	ARTICLE	IF	CITATIONS
199	Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area. International Journal of Cardiology, 2017, 243, 211-215.	1.7	21
200	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Subanalysis From the PREFER in AF (Prevention of Thromboembolism and Bleeding Outcomes in Very Elderly Patients With Atrial Fibrillation) Trial. JAMA, 2017, 317, 187-197.	3.7	187
201	Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin. Journal of the American Heart Association, 2017, 6, .	3.7	2
202	Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. Journal of the American Association of Nurse Practitioners, 2017, 29, 551-561.	0.9	5
203	Antithrombotic treatment for ischaemic stroke. British Journal of Neuroscience Nursing, 2017, 13, S26-S34.	0.2	0
204	Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 12-18.	1.9	34
205	Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. Contemporary Clinical Trials, 2017, 60, 51-55.	1.8	0
207	Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 31-37.e13.	0.4	77
208	APPROACHES TO ANTITHROMBOTIC THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2017, 13, 275-283.	0.8	1
209	Antithrombotic treatment for ischaemic stroke. NursePrescribing, 2017, 15, 345-354.	0.1	0
210	The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China. International Journal of General Medicine, 2017, Volume 10, 69-77.	1.8	9
211	Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. Clinical Interventions in Aging, 2017, Volume 12, 175-187.	2.9	10
212	Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed. BMC Cardiovascular Disorders, 2017, 17, 260.	1.7	4
213	ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY. Rational Pharmacotherapy in Cardiology, 2017, 13, 124-128.	0.8	0
214	A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation. Medicine (United States), 2018, 97, e9578.	1.0	6
215	Managing anticoagulation in patients receiving implantable cardiac devices. Future Cardiology, 2018, 14, 151-164.	1.2	1
216	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology and Therapeutics, 2018, 104, 301-310.	4.7	25
217	Poisoning in elderly. Indian Journal of Medical Specialities, 2018, 9, 113-117.	0.1	2

#	ARTICLE	IF	CITATIONS
218	Coronary Artery Disease in Patients ≥80 Years of Age. Journal of the American College of Cardiology, 2018, 71, 2015-2040.	2.8	175
219	Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: The Emergency Physician Perspective. Canadian Journal of Cardiology, 2018, 34, 125-131.	1.7	11
220	Retrospective Evaluation of the Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation. Journal of Veterinary Internal Medicine, 2018, 32, 86-92.	1.6	24
223	Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular. Medicina Clínica, 2018, 150, 8-24.	0.6	2
224	Thrombosis in Atrial Fibrillation. , 2018, , 337-354.		0
225	Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation. Monaldi Archives for Chest Disease, 2018, 88, 958.	0.6	5
226	Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. Western Journal of Emergency Medicine, 2018, 19, 346-360.	1.1	11
227	Screening for Atrial Fibrillation With Electrocardiography. JAMA - Journal of the American Medical Association, 2018, 320, 485.	7.4	94
228	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. International Journal of Cardiology, 2018, 265, 118-124.	1.7	18
229	New Oral Anticoagulants: An Update. Journal of Bangladesh College of Physicians & Surgeons, 2019, 37, 135-150.	0.1	0
230	Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
231	Stroke risk stratification in atrial fibrillation: a review of common risk factors. Journal of Community Hospital Internal Medicine Perspectives, 2019, 9, 113-120.	0.8	38
232	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS ONE, 2019, 14, e0211766.	2.5	26
233	Atrial fibrillation and stroke: a practical guide. Practical Neurology, 2019, 19, 208-224.	1.1	16
234	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood, 2019, 133, 2269-2278.	1.4	15
235	Second look Holter ECG in neurorehabilitation. Neurological Research and Practice, 2019, 1, 41.	2.0	2
236	Stroke in the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.8	27
237	Stroke prevention in atrial fibrillation: State of the art. International Journal of Cardiology, 2019, 287, 201-209.	1.7	13

#	ARTICLE	IF	CITATIONS
238	Anticoagulation in the cardiac patient: A concise review. European Journal of Haematology, 2019, 102, 3-19.	2.2	9
239	Risk Stratification in Atrial Fibrillation. , 2019, , 47-66.		0
240	Oral Anticoagulation in the Elderly: New Oral Anticoagulantsâ€“Innovative Solution for an Old Problem?. American Journal of Therapeutics, 2019, 26, e133-e142.	0.9	5
241	To Your Health: Health Insurance, Selfâ€“Employment Exit, and Older Entrepreneurs. Journal of Small Business Management, 2019, 57, 593-615.	4.8	5
242	Comparison in Patients < 75 Years of Age - Versus â€“ Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German) Tj ETQq0 0 0 rgBT1,6 Overlock100 Tf 50 5	1.0	100
243	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data. Revista Portuguesa De Cardiologia, 2020, 39, 651-662.	0.5	2
244	Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation. Scientific Reports, 2020, 10, 20144.	3.3	2
245	Treatment of older patients with atrial fibrillation by morbidity burden. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 23-30.	4.0	9
246	Clinical Outcomes of Direct Oral Anticoagulants and Warfarin in Japanese Patients with Atrial Fibrillation Agedâ€“â‰¥85 Years: A Single-Center Observational Study. Drugs - Real World Outcomes, 2020, 67, 325-335.	0.7	3
247	Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A populationâ€“based study. Journal of Cardiovascular Electrophysiology, 2020, 31, 1356-1363.	1.7	4
248	Evaluation of risk factors and drug adherence in the occurrence of stroke in patients with atrial fibrillation. Pharmacy Practice, 2020, 18, 1860.	1.5	5
249	Stroke prevention in elderly patients with nonâ€“valvular atrial fibrillation in the BALKANâ€“AF survey. European Journal of Clinical Investigation, 2020, 50, e13200.	3.4	5
250	Association of <scp>CHA₂</sub>DS₂</sub>â€“VASc</scp> Score with Stroke, Thromboembolism, and Death in Hip Fracture Patients. Journal of the American Geriatrics Society, 2020, 68, 1698-1705.	2.6	7
251	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Annals of Medicine, 2021, 53, 17-25.	3.8	18
252	Anticoagulation in atrial fibrillation. Heart, 2021, 107, 419-427.	2.9	9
253	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE, 2021, 16, e0249524.	2.5	6
254	Stroke Prevention: Little-Known and Neglected Aspects. Cerebrovascular Diseases, 2021, 50, 622-635.	1.7	6
255	AFCNNet: Automated detection of AF using chirplet transform and deep convolutional bidirectional long short term memory network with ECG signals. Computers in Biology and Medicine, 2021, 137, 104783.	7.0	40

#	ARTICLE	IF	CITATIONS
256	Neurologic complications of atrial fibrillation: Pharmacologic and interventional approaches to stroke prevention. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 143-149.	1.8	1
257	NHG-Standaard Atriumfibrilleren. , 2011, , 313-339.		2
258	Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation. Journal of Geriatric Cardiology, 2017, 14, 743-749.	0.2	14
259	Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Texas Heart Institute Journal, 2016, 43, 287-290.	0.3	10
260	Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatolian Journal of Cardiology, 2018, 19, 67-71.	0.9	28
261	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. International Journal of General Medicine, 2013, 6, 167.	1.8	16
262	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 87-109.	0.3	8
264	Preventative Measures of Stroke in Patients With Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 399.	0.5	2
265	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants. Journal of Atrial Fibrillation, 2013, 6, 783.	0.5	19
266	Direct oral anticoagulants for secondary stroke prevention in patients over 80Âyears of age: the role of geriatric functional status. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	0
267	Reviewing a patient's secondary prevention treatment. Independent Nurse, 2009, 2009, .	0.1	0
271	Atrial Fibrillation and Heart Failure in the Aging Population. , 2014, , 65-84.		0
273	Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease. British Journal of Medicine and Medical Research, 2016, 13, 1-9.	0.2	0
274	Recurrence of Stroke in Patients with AF Using NOACs. , 2017, , 11-23.		0
275	Choosing an Anticoagulant in an Elderly Patient. , 2017, , 19-24.		0
276	Cardioembolic Stroke. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 111-132.	0.8	14
277	Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. , 2018, , 73-89.		0
278	Prevention and Treatment of Bleeding Complications in Dermatologic Surgery. , 2019, , 1141-1155.		0

#	ARTICLE	IF	CITATIONS
279	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine, 2019, 5, 10-22.	0.4	0
280	Influence of ageism on guideline adherence in seniors with atrial fibrillation in the local practise of private cardiology clinic among years 2012 a 2017. Vnitri Lekarstvi, 2020, 66, e5-e11.	0.2	0
281	Using mobile ECG devices to increase detection of atrial fibrillation across a range of settings in south London. Future Healthcare Journal, 2020, 7, 86-89.	1.4	1
282	New Insights into Anticoagulation in Atrial Fibrillation. Journal of Arrhythmia, 2011, 27, 186-192.	1.2	0
283	Efficacy and safety of rivaroxaban for secondary prevention in non-valvular atrial fibrillation after cardioembolic stroke complicated by hemorrhagic transformation: a case report with a 3-year follow-up. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2020, 179, .	0.1	0
284	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 651-662.	0.2	0
285	Anticoagulation for stroke prevention in elderly patients with atrial fibrillation: risk-benefit ratio remains highly favorable. Journal of Vascular and Interventional Neurology, 2010, 3, 31-2.	1.1	1
286	Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. , 2012, 3, 339-51.		7
287	Stroke And Bleeding Risk Assessment: Where Are We Now?. Journal of Atrial Fibrillation, 2014, 6, 1042.	0.5	1
288	Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 586.	0.5	2
289	The Introduction of Direct Oral Anticoagulants Has Not Resolved Treatment Gaps for Frail Patients With Nonvalvular Atrial Fibrillation. Canadian Journal of Cardiology, 2022, 38, 77-84.	1.7	18
290	Screening for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2022, 327, 368.	7.4	23
291	MEDEX South Carolina: a progress report. The Journal of the South Carolina Medical Association, 1975, 71, 337-8.	0.0	0
292	Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210746.	1.7	3
293	Artificial intelligence and atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2022, 33, 1932-1943.	1.7	10
294	EGb 761Â® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimerâ€™s Dementiaâ€™Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial. Healthcare (Switzerland), 2021, 9, 1678.	2.0	3
299	Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis. American Heart Journal, 2022, 250, 66-75.	2.7	2
300	Contemporary Practice and Optimising Referral Pathways for Implantable Cardiac Monitoring for Atrial Fibrillation after Cryptogenic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106474.	1.6	3

#	ARTICLE	IF	CITATIONS
301	Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database. Journal of Interventional Cardiac Electrophysiology, 0, , .	1.3	4
302	Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation. Annals of Internal Medicine, 2022, 175, 1230-1239.	3.9	6
303	Treatment patterns for oral anticoagulants in older patients with atrial fibrillation: a retrospective, cross-sectional, nationwide study from Denmark. BMJ Open, 2022, 12, e062353.	1.9	0
304	Barriers to Guideline-Directed Anticoagulation in Patients With Atrial Fibrillation: New Approaches to an Old Problem. Canadian Journal of Cardiology, 2023, 39, 625-636.	1.7	3
305	Relationship Between Direct Oral Anticoagulant Doses and Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillationâ€”ANAFIE Registry Sub-Analysis â€”. Circulation Journal, 2023, , .	1.6	1
306	Left atrial appendage closure in very elderly patients in the French National Registry. Heart, 2024, 110, 245-253.	2.9	0